Skip to main content

Table 1 Baseline demographic characteristics and outcome measures

From: The effect of choline-stabilized orthosilicic acid in patients with peri-implantitis: an exploratory randomized, double-blind, placebo controlled study

Variable Treatment group p value
Placebo CS-OSA
Number of patients 10 8  
Number of implants 20 16  
Age 51.50 ± 10.19 52.50 ± 7.29 0.818
Number of males 3 5 0.168
PPD (mm) 5.04 ± 2.37 6.01 ± 2.54 0.009
REC (mm) 0.78 ± 1.27 0.70 ± 1.22 0.577
BOP (%) 86.67 ± 34.14 94.79 ± 22.34 0.045
IS-AC (mm)# 2.57 ± 2.56 2.4 ± 2.19 0.765
IS-BIC (mm)# 3.83 ± 2.39 4.43 ± 1.98 0.467
OHIP Total 15.10 ± 10.81 14.63 ± 8.35 0.515
hsCRP (mg/L) 2.40 ± 2.40 4.12 ± 2.83 0.055
Osteocalcin (ng/mL) 9.04 ± 3.39 9.88 ± 3.67 0.762
BAP (µg/L) 10.22 ± 4.20 10.13 ± 1.58 0.203
CTX-I (ng/mL) 0.48 ± 0.22 0.52 ± 0.23 0.696
PINP (ng/mL) 43.35 ± 12.61 47.03 ± 8.51 0.573
  1. Data expressed as mean ± SD. Significant difference between groups: p < 0.05 = significant (bold) #IS-AC and IS-BIC analysis was performed on cone beam computed tomography (CBCT) scans of sufficient quality (i.e. without artefacts) taken from 9 patients (19 implants) in the placebo group and 6 patients (7 implants) in the CS-OSA group. CS-OSA: choline-stabilized orthosilicic acid, PPD: probing pocket depth, REC: mucosal recession, BOP: bleeding on probing, IS-AC: distance from implant shoulder to alveolar crest, IS-BIC: distance from implant shoulder to first bone-to-implant contact, OHIP: patient’s oral health related quality of life questionnaire, hsCRP: high sensitive C-reactive protein, BAP: bone alkaline phosphatase, CTX-I: C-terminal telopeptide of collagen I, PINP: N-terminal propeptide of type I procollagen